Invemed Associates

Kenneth Langone, the founder and chairman, has historically been the central decision-maker for the firm's principal investments. The firm operates with a lean structure built around his network and analytical team in New York. No public succession plan or investment committee structure has been disclosed.

Sourcing relies on Ken Langone's six-decade network of corporate executives, board relationships, and Wall Street contacts. The firm does not run a proprietary outbound origination engine or partner network like a growth equity fund. Specific deal terms, such as the early investment in Home Depot, originated through Langone's direct relationships with founders before the companies went public.

Invemed operates as a registered broker-dealer and investment bank that also makes merchant-banking investments with the founder's capital. While it manages wealth for Langone, it is not structured as a single family office because it actively executes institutional brokerage trades and takes on banking mandates for third-party corporate clients.

Outside capital can participate on a deal-by-deal basis through co-investment structures, but the firm has never marketed a blind-pool fund to institutional limited partners. The capital base remains anchored by Langone's personal assets. Third-party capital has historically arrived through discrete syndicates of high-net-worth individuals, not institutional fundraising cycles.

Kenneth Langone is a major benefactor and the namesake of NYU Langone Health, having contributed hundreds of millions of dollars to NYU's medical center. Invemed itself has no operational linkage to the hospital. The philanthropy is structured separately through the Langone family's charitable vehicles rather than through the investment firm.

The firm targets public equities, PIPEs, and late-stage private companies, avoiding venture-stage startups. Structures range from open-market common-stock accumulation to structured preferred-equity investments. Invemed's public history includes serving as a placement agent and lead investor in significant corporate recapitalizations, although its specific current pipeline is not public.

Because Langone has never pursued a business model built on institutional fund management fees, there is no regulatory or marketing requirement to flash an AUM number. The firm blends proprietary capital with ad hoc co-investor capital, making a static AUM figure potentially misleading about its actual buying power, which can scale opportunistically through Langone's personal liquidity and network.